# US 2010/0136695 A1 · Double-stranded oligonucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136695 A1
- Document ID: US20100136695A1
- Status: Published application
- Kind: A1
- Application number: 12/062,380
- Filed: 2008-04-03
- Published: 2010-06-03
- Earliest claimed: 2002-02-01
- Assignees: Invitrogen Corporation
- Inventors: Tod M. Woolf
- Web page: https://patentgrep.com/patent/US20100136695A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 207/11022: Cyclin-dependent kinase (2.7.11.22)
- C12Y 301/03048: Protein-tyrosine-phosphatase (3.1.3.48)
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/33: of the base
- C12N 2310/351: Conjugate
- C12N 2310/53: partially self-complementary or closed
- C12N 2320/31: Combination therapy
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.

## Claims

### Claim 1

A method for introducing a double-stranded ribonucleic acid molecule comprising a first strand and a second strand into a eukaryotic cell in vitro, the method comprising contacting the eukaryotic cell with the double-stranded ribonucleic nucleic acid molecule,
wherein from one to six of the nucleotides of the first strand of the double-stranded ribonucleic acid molecule are chemically modified at the 2′ positions, wherein said modification is a 2′-O-methyl modification;
wherein from one to six of the nucleotides of the second strand of the double-stranded ribonucleic acid molecule are chemically modified at the 2′ positions, wherein said modification is a 2′-O-methyl modification;
wherein the double-stranded ribonucleic acid molecule is between 18 and 30 nucleosides in length;
wherein at least one of the first strand or the second strand contains a 5′-terminal phosphorus containing moiety; and
wherein the double-stranded nucleic acid molecule is introduced into the eukaryotic cell and participates in RNA interference mediated degradation of RNA which shares sequence complementarity with at least one strand of the double-stranded nucleic acid molecule.

### Claim 2 (depends on 1)

The method of claim 1, wherein the double-stranded ribonucleic acid molecule is between 20 and 30 nucleosides in length.

### Claim 3 (depends on 1)

The method of claim 1, wherein the double-stranded ribonucleic acid molecule is 25 nucleosides in length.

### Claim 4 (depends on 1)

The method of claim 1, wherein the double-stranded ribonucleic acid molecule contains an overhang of at least one nucleoside on at least one end.

### Claim 5 (depends on 4)

The method of claim 4, wherein the overhang is a 3′ end overhang.

### Claim 6 (depends on 4)

The method of claim 4, wherein the nucleosides of the 3′ end overhang are deoxy T-deoxy T.

### Claim at position 7

-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the eukaryotic cell is contacted with the double-stranded ribonucleic acid molecule in the presence of a transfection agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the transfection reagent is a cationic lipid.

### Claim 11 (depends on 1)

The method of claim 1, wherein the double-stranded ribonucleic acid molecule is introduced into the eukaryotic cell by electroporation.

### Claim 12 (depends on 1)

The method of claim 1, wherein a strand of said double-stranded ribonucleic acid molecule is complementary to a sequence of an mRNA expressed in said eukaryotic cell.

### Claim 13

(canceled)

### Claim 14

A method for introducing a double-stranded ribonucleic acid molecule comprising a first strand and a second strand into a eukaryotic cell in vitro, the method comprising contacting the eukaryotic cell with the double-stranded ribonucleic acid molecule,
wherein at least one of the nucleomonomers of the first strand or the second strand of the double-stranded ribonucleic acid molecule is chemically modified at the 2′ position, wherein said modification is a 2′-O-methyl modification;
wherein the first strand and the second strand each have a length of less than 25 nucleomonomers and have a duplex length of at least 10 to at least 24 nucleomonomers;
wherein at least one of the first strand or the second strand contains a 5′-terminal phosphorus containing moiety; and
wherein the double-stranded nucleic acid molecule is introduced into the eukaryotic cell and participates in RNA interference mediated degradation of RNA which shares sequence complementarity with at least one strand of the double-stranded nucleic acid molecule.

### Claim 15 (depends on 14)

The method of claim 14, wherein the double-stranded ribonucleic acid molecule contains an overhang of at least one nucleomonomer on at least one end.

### Claim 16 (depends on 15)

The method of claim 15, wherein the overhang is a 3′ end overhang.

### Claim 17 (depends on 16)

The method of claim 16, wherein the nucleomonomers of the 3′ end overhang are deoxy T-deoxy T.
